Ionis Pharmaceuticals annual cash and equivalents
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ionis Pharmaceuticals Cash & Equivalents Growth & History (IONS)
Ionis Pharmaceuticals's cash and equivalents was $372.3M for fiscal 2025.
View full Ionis Pharmaceuticals company overviewIonis Pharmaceuticals annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $372.3M | $130.2M | +53.78% |
| 2024 | 2024-12-31 | $242.1M | −$157.2M | −39.37% |
| 2023 | 2023-12-31 | $399.3M | $122.8M | +44.41% |
| 2022 | 2022-12-31 | $276.5M | −$592.7M | −68.19% |
| 2021 | 2021-12-31 | $869.2M | $471.5M | +118.57% |
| 2020 | 2020-12-31 | $397.7M | −$285.6M | −41.80% |
| 2019 | 2019-12-31 | $683.3M | $404.5M | +145.06% |
| 2018 | 2018-12-31 | $278.8M | $149.2M | +115.09% |
| 2017 | 2017-12-31 | $129.6M | $44.9M | +53.07% |
| 2016 | 2016-12-31 | $84.7M | −$44.1M | −34.25% |
| 2015 | 2015-12-31 | $128.8M | −$14.2M | −9.93% |
| 2014 | 2014-12-31 | $143.0M | −$17.0M | −10.61% |
| 2013 | 2013-12-31 | $160.0M | $35.5M | +28.51% |
| 2012 | 2012-12-31 | $124.5M | $59.0M | +90.12% |
| 2011 | 2011-12-31 | $65.5M | −$4.6M | −6.53% |
| 2010 | 2010-12-31 | $70.1M | −$35.2M | −33.45% |
| 2009 | 2009-12-31 | $105.3M | −$118.7M | −53.01% |
| 2008 | 2008-12-31 | $224.0M | — | — |
Ionis Pharmaceuticals quarterly cash and equivalents
Q4.09
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $350.1M | $52.8M | +17.75% |
| Q1 2026 | 2026-03-31 | $173.4M | −$90.8M | −34.37% |
| Q4 2025 | 2025-12-31 | $372.3M | $130.2M | +53.78% |
| Q3 2025 | 2025-09-30 | $338.3M | $3.7M | +1.12% |
| Q2 2025 | 2025-06-30 | $297.3M | $3.3M | +1.13% |
| Q1 2025 | 2025-03-31 | $264.2M | −$84.7M | −24.28% |
| Q4 2024 | 2024-12-31 | $242.1M | −$157.2M | −39.37% |
| Q3 2024 | 2024-09-30 | $334.6M | −$17.5M | −4.96% |
| Q2 2024 | 2024-06-30 | $294.0M | −$130.8M | −30.79% |
| Q1 2024 | 2024-03-31 | $348.9M | $39.9M | +12.90% |
| Q4 2023 | 2023-12-31 | $399.3M | $122.8M | +44.41% |
| Q3 2023 | 2023-09-30 | $352.1M | $37.1M | +11.77% |
| Q2 2023 | 2023-06-30 | $424.8M | −$97.1M | −18.61% |
| Q1 2023 | 2023-03-31 | $309.0M | −$233.5M | −43.04% |
| Q4 2022 | 2022-12-31 | $276.5M | −$592.7M | −68.19% |
| Q3 2022 | 2022-09-30 | $315.0M | −$318.0M | −50.23% |
| Q2 2022 | 2022-06-30 | $521.9M | −$43.2M | −7.64% |
| Q1 2022 | 2022-03-31 | $542.5M | $128.4M | +30.99% |
| Q4 2021 | 2021-12-31 | $869.2M | $471.5M | +118.57% |
| Q3 2021 | 2021-09-30 | $633.0M | −$106,000 | −0.02% |
| Q2 2021 | 2021-06-30 | $565.1M | $34.9M | +6.59% |
| Q1 2021 | 2021-03-31 | $414.2M | −$72.0M | −14.82% |
| Q4 2020 | 2020-12-31 | $397.7M | −$285.6M | −41.80% |
| Q3 2020 | 2020-09-30 | $633.1M | $385.1M | +155.33% |
| Q2 2020 | 2020-06-30 | $530.2M | $257.7M | +94.55% |
| Q1 2020 | 2020-03-31 | $486.2M | $110.4M | +29.37% |
| Q4 2019 | 2019-12-31 | $683.3M | $404.5M | +145.06% |
| Q3 2019 | 2019-09-30 | $247.9M | −$232.0M | −48.33% |
| Q2 2019 | 2019-06-30 | $272.5M | −$533.0M | −66.17% |
| Q1 2019 | 2019-03-31 | $375.8M | $148.3M | +65.19% |
| Q4 2018 | 2018-12-31 | $278.8M | $149.2M | +115.09% |
| Q3 2018 | 2018-09-30 | $479.9M | $320.7M | +201.47% |
| Q2 2018 | 2018-06-30 | $805.5M | $672.5M | +505.67% |
| Q1 2018 | 2018-03-31 | $227.5M | $113.3M | +99.18% |
| Q4 2017 | 2017-12-31 | $129.6M | $44.9M | +53.07% |
| Q3 2017 | 2017-09-30 | $159.2M | $74.9M | +88.89% |
| Q2 2017 | 2017-06-30 | $133.0M | $20.5M | +18.18% |
| Q1 2017 | 2017-03-31 | $114.2M | $20.9M | +22.37% |
| Q4 2016 | 2016-12-31 | $84.7M | −$44.1M | −34.25% |
| Q3 2016 | 2016-09-30 | $84.3M | −$42.3M | −33.43% |
| Q2 2016 | 2016-06-30 | $112.5M | −$7.0M | −5.82% |
| Q1 2016 | 2016-03-31 | $93.3M | −$55.0M | −37.08% |
| Q4 2015 | 2015-12-31 | $128.8M | −$14.2M | −9.93% |
| Q3 2015 | 2015-09-30 | $126.6M | $53.4M | +72.89% |
| Q2 2015 | 2015-06-30 | $119.5M | $25.4M | +27.00% |
| Q1 2015 | 2015-03-31 | $148.3M | −$13.4M | −8.30% |
| Q4 2014 | 2014-12-31 | $143.0M | −$17.0M | −10.61% |
| Q3 2014 | 2014-09-30 | $73.2M | −$183.2M | −71.44% |
| Q2 2014 | 2014-06-30 | $94.1M | −$202.5M | −68.27% |
| Q1 2014 | 2014-03-31 | $161.8M | $54.1M | +50.28% |
| Q4 2013 | 2013-12-31 | $160.0M | $35.5M | +28.51% |
| Q3 2013 | 2013-09-30 | $256.4M | $171.8M | +203.22% |
| Q2 2013 | 2013-06-30 | $296.5M | $210.9M | +246.24% |
| Q1 2013 | 2013-03-31 | $107.7M | $51.3M | +90.90% |
| Q4 2012 | 2012-12-31 | $124.5M | $59.0M | +90.12% |
| Q3 2012 | 2012-09-30 | $84.6M | $29.3M | +53.02% |
| Q2 2012 | 2012-06-30 | $85.6M | $623,000 | +0.73% |
| Q1 2012 | 2012-03-31 | $56.4M | −$29.8M | −34.58% |
| Q4 2011 | 2011-12-31 | $65.5M | −$4.6M | −6.53% |
| Q3 2011 | 2011-09-30 | $55.3M | −$44.9M | −44.80% |
| Q2 2011 | 2011-06-30 | $85.0M | $39.0M | +84.68% |
| Q1 2011 | 2011-03-31 | $86.2M | — | — |
| Q4 2010 | 2010-12-31 | $70.1M | −$35.2M | −33.45% |
| Q3 2010 | 2010-09-30 | $100.1M | — | — |
| Q2 2010 | 2010-06-30 | $46.0M | — | — |
| Q4 2009 | 2009-12-31 | $105.3M | — | — |
Ionis Pharmaceuticals cash and equivalents trends
Over the last five fiscal years, Ionis Pharmaceuticals's cash and equivalents decreased from $397.7M to $372.3M, a change of −$25.4M. The latest reported quarter, Q2 2026, shows $350.1M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ionis Pharmaceuticals source filings ↗Community posts
Roche quantifies proteinuria reduction for Ionis-licensed sefaxersen
Ionis ($IONS) reported new detailed results from partner Roche’s Phase 3 IMAgINATION trial of sefaxersen in IgA nephropathy. The investigational monthly injection reduced urine protein-to-creatinine ratio by 43.1% versus placebo at 37 weeks ...
